The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Khodakova Iu.V.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Rozhinskaia L.Ia.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Sukhanova G.A.

Gematologicheskiĭ nauchnyĭ tsentr, Moskva

Arapova S.D.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Il'in A.V.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Chirkova L.D.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Endogenous hypercorticism as a prothrombogenic state

Authors:

Khodakova Iu.V., Rozhinskaia L.Ia., Sukhanova G.A., Arapova S.D., Il'in A.V., Chirkova L.D.

More about the authors

Journal: Problems of Endocrinology. 2012;58(1): 3‑8

Views: 666

Downloaded: 6

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Khodakova IuV, Rozhinskaia LIa, Sukhanova GA, Arapova SD, Il'in AV, Chirkova LD. Endogenous hypercorticism as a prothrombogenic state. Problems of Endocrinology. 2012;58(1):3‑8. (In Russ.)

МСФ на ЯМ
Close metadata
Recommended articles:
The rela­tionship between the deve­lopment of post-stroke cognitive impairment and changes in the coagulation component of hemo­stasis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):23-29
The multidirectional effe­cts of thro­mbin and the possibility of their control in neurology. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):42-48
Asso­ciations between components of meta­bolic syndrome and cognitive impairment in patients with schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):82-87
Expe­rimental and morphological vali­dation of Molselect G-50 sorbent for treating traumatic liver ruptures. Russian Journal of Evidence-Based Gastroenterology. 2024;(1):12-20
Cere­bral hemo­dynamic diso­rders in patients with schi­zophrenia with concomitant meta­bolic syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):80-85
Predictors of effe­ctive complex physiotherapy in patients with skin invo­lution. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(1):13-20
Serum uric acid — a meta­bolic marker of non-alcoholic fatty liver disease. Russian Journal of Evidence-Based Gastroenterology. 2024;(2):36-42
Asse­ssment of the condition of organs and tissues of the oral cavity in people with dentition defe­cts against the background of meta­bolic syndrome. Stomatology. 2024;(3):31-38
A personalized application of therapeutic physical factors in patients with meta­bolic syndrome. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(2):5-11
Skin alte­rations as possible clinical markers of diabetes mellitus and meta­bolic syndrome. Russian Journal of Preventive Medi­cine. 2024;(7):101-107

The patients in the active phase of endogenous hypercorticism not infrequently present with hypercoagulation syndrome characterized by abnormal blood clotting in conjunction with slowed fibrinolysis, elevated fibrinogen and D-dimer concentrations. In addition, such patients exhibit endotheliosis manifest as a rise in the PAI-1 and Willebrand factor levels. The remission of the Cushing's disease (CD) is associated with a higher fibrinogen, thrombomodulin, endothelin-1, and D-dimer levels compared with CD patients in the active phase of this disease and healthy subjects (control). This suggests the continuing progression of endotheliosis, enhanced thrombogenicity, and the increased risk of cardiovascular complications.

Keywords:

Cushing's disease
metabolic syndrome
hemostasis
fibrinolysis
endotheliosi

Authors:

Khodakova Iu.V.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Rozhinskaia L.Ia.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Sukhanova G.A.

Gematologicheskiĭ nauchnyĭ tsentr, Moskva

Arapova S.D.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Il'in A.V.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Chirkova L.D.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

List of references:

  1. Goncharov N.P., Kolesnikova G.S, Todua T.N., Rozhinskaya L.Ya., Marova E.I. Steroidogenez v kore nadpochechnikov i sekretsiya nadpochechnikovykh androgenov pri bolezni i sindrome Itsenko-Kushinga. Problemy endokrinologii 2007; 53: 1: 26-29.
  2. Dolgov V.V., Svirin P.V. Laboratornaya diagnostika narushenii gemostaza. M-Tver':Triada 2005; 44-49, 59-64.
  3. Lupinskaya Z.A. Endotelii sosudov - osnovnoi regulyator mestnogo krovotoka. Vestnik KRSU 2003; 7.
  4. Marova E.I., Arapova S.D., Bel'chenko L.V. Bolezn' Itsenko-Kushinga. Metodicheskoe posobie dlya vrachei. M 2000.
  5. Melkumyan A.L., Morozov K.M. i dr. Faktory riska sistemy gemostaza pri zabolevaniyakh aorty, magistral'nykh i perifericheskikh sosudov. Metodicheskoe posobie dlya vrachei. M 2001.
  6. Petrishchev N.N., Vlasov T.D., Kapitonova O.A. Endotelial'naya disfunktsiya i metody ee korrektsii. Materialy Assamblei "Vrach-Provizor-Patsient" 2003; 57.
  7. Petrishchev N.N., Vlasov T.D. Fiziologiya i patofiziologiya endoteliya. Sbornik statei. Disfunktsiya endoteliya. Prichiny, mekhanizmy, farmakologicheskaya korrektsiya. Pod red. N.N. Petrishcheva. M 2003; 4-38.
  8. Sukhanova G.A. Trombofilii kak faktor razvitiya tromboticheskikh sostoyanii. V kn.: Ocherki po proizvodstvennoi i klinicheskoi transfuziologii. Pod red. A.I. Vorob'eva. M: N'yudiamed ;364-372.
  9. Sukhanova G.A., Rudakova V.E., Vasil'ev S.A. Profilaktika tromboembolicheskikh oslozhnenii u lits srednego i pozhilogo vozrasta. Klin gerontol 2007; 4: 10-15.
  10. Shiffman F.Dzh. Patofiziologiya sistemy krovi. Pod red. Yu.V. Natochina. SPb: Nevskii dialekt 2001; 191-214, 253-269.
  11. Akaza I., Yoshimoto T., Tsuchiya K., Hirata Y. Endothelial Dysfunction Associated with Hypercortisolism is Reversible in Cushing's Syndrome. Endocr J 2009.
  12. Alessi M.C., Juhan-Vague I. Contribution of PAI-1 in cardiovascular pathology. Arch Mal Coeur Vaiss 2004; 97: 6: 673-678.
  13. Ambrosi B., Sartorio A., Pizzocaro A., Passini E., Bottasso B., Federici A. Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentaloma. Exp Clin Endocrinol Diabet 2000; 108: 4: 294-298.
  14. Arnaldi G., Mancini T., Polenta V., Boscara M. Cardiovascular risk in Cushing's syndrom. Pituitary 2004; 7: 253-256.
  15. Boscaro M., Sonino N., Scarda A., Barzon L., Fallo F., Sartori M.T., Patrassi G.M., Girolami A. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab 2002; 87: 8: 3662-3666.
  16. Brotman D.J., Girod J.P., Garcia M.J. et al. Effects of short-term glucocorticoids on cardiovascular biomarkers. J Clin Endocrin Metab 2005; 90: 3202-3208.
  17. Casonato A., Daidone V., Sartorello F., Albiger N., Romualdi C., Mantero F., Pagnan A., Scaroni S. Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoid-induced increase in von Willebrand factor: the lesson learned from Cushing syndrome. Br J Haematol 2008; 140: 2: 230-235.
  18. Colao A., Pivonello R., Spiezia S., Faggiano A., Ferone D., Filippella M., Marzullo P., Cerbone G., Siciliani M., Lombardi G. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 1999; 84: 8: 2664-2672.
  19. Dover A.R., Hadoke P.W., Walker B.R., Newby D.E. Acute effects of glucocorticoids on endothelial fibrinolytic and vasodilator function in humans. J Cardiovasc Pharmacol 2007; 50: 3: 321-326.
  20. Erbil Y., Ademoğlu E., Ozbey N., Barbaras U., Yanik V.T., Salmaslioglu A., Bozbora A., Ozarmağan S. Evaluation of the cardiovascular risk in patients with subclinical Cushing syndrome before and after surgery. World J Surg 2006; 30: 9: 1665-1667.
  21. Erem C., Nuhoglu I., Yilmaz M., Kocak M., Demirel A., Ucuncu O., Onder Ersoz H. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels. J Endocrinol Invest 2009; 32: 2: 169-174.
  22. Extabe J., Vazquez J.A. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994; 40: 479-484.
  23. Faggiano A., Pivonello R., Spiezia S., De Martino M.C., Filippella M., Di Somma C., Lombardi G., Colao A. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003; 88: 6: 2527-2533.
  24. Fatti L.M., Bottasso B., Invitti C., Coppola R., Cavagnini F., Mannucci P.M. Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome. J Endocrinol Invest 2000; 23: 3: 145-150.
  25. Jacoby R.C., Owings J.T, Ortega T. et al. Biochemical basis for hypercoagulable state seen in Cushing syndrome; discussion 1006-1007. Arch Surg 2001; 136: 9: 1003-1006.
  26. Jezkova J., Marek J., Prazny M., Krsek M., Malickova K., Rosicka M., Jarkovska Z., Pecen L. Effect of hypercortisolism on development of atherosclerotic changes in blood vessels. Vnitr Lek 2003; 49: 8: 656-667.
  27. Johansson L., Jansson J.H., Boman K., Nilsson T.K., Stegmayr B., Hallmans G. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 2000; 31: 1: 26-32.
  28. Juhan-Vague I., Morange P., Alessi C.M. Fibrinolytic function and coronary risk. Curr Cardiol Rep 1999; 1: 2: 119-124.
  29. Kastelan D., Dusek T., Kraljevic I., Polasek O., Giljevic Z., Solak M., Salek S.Z., Jelcic J., Aganovic I., Korsic M. Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine 2009; 36: l: 70-74.
  30. Kirilov G., Tomova A., Dakovska L., Kumanov P., Shinkov A., Alexandrov A.S. Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing's syndrome. Eur J Endocrinol 2003; 149: 6: 549-553.
  31. Kristo C., Ueland T., Godang K., Aukrust P., Bollerslev J. Biochemical markers for cardiovascular risk following treatment in endogenous Cushing's syndrome. J Endocrinol Invest 2008; 31: 5: 400-405.
  32. La Brocca A., Terzolo M., Pia A., Paccotti P., De Giulli P., Angeli A. Reccurent thromboembolism as a hallmark of Cushing's syndrome. J Endocrinol Invest 1997; 20: 4: 211-214.
  33. Lindholm J., Juul S. et al. Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab 2001; 86: 1: 117-123.
  34. Mancini T., Kola B., Mantero F., Boscaro M., Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf) 2004; 61: 6: 768-777.
  35. Manetti L., Bogazzi F., Giovannetti C., Raffaelli V., Genovesi M., Pellegrini G., Ruocco L., Iannelli A., Martino E. Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome:' results from a prospective study before and after surgery. Department of Endocrinology, University of Pisa, Ospedale Cisanello. Eur J Endocrinol 2010; 163: 5: 783-791.
  36. Patrassi G.M., Sartori M.T., Viero M.L., Scarano L., Boscaro M., Girolami A. The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state. Blood Coagul Fibrinolysis 1992; 3: 6: 789-793.
  37. Pivonello R., De Martino M.C., De Leo M., Tauchmanová L., Faggiano A., Lombardi G., Colao A. Cushing's syndrome: aftermath of the cure. Arq Bras Endocrinol Metabol 2007; 51: 8: 1381-1391.
  38. Prázný M., Jezková J., Horová E., Lázarová V., Hána V., Kvasnicka J., Pecen L., Marek J., Skrha J., Krsek M. Impaired microvascular reactivity and endothelial function in patients with Cushing's syndrome: influence of arterial hypertension. Physiol Res 2008; 57: l: 13-22.
  39. Trementino L., Arnaldi G., Appolloni G., Daidone V., Scaroni C., Casonato A., Boscaro M. Coagulopathy in Cushing's Syndrome. Neuroendocrinology 2010; 92: Suppl 1: 55-59.
  40. Van Zaane B., Nur E., Squizzato A., Dekkers O.M., Twickler M.T., Fliers E., Gerdes V.E., Biiller H.R., Brandjes D.P. Hypercoagulable state in Cushing's syndrome: a systematic review. J Clin Endocrinol Metab 2009; 94: 8: 2743-2750.
  41. Verhamme P., Hoylaerts M.F. The pivotal role of the endothelium in haemostasis and thrombosis. Acta Clin Belg 2006; 61: 5: 213-219.
  42. Vaughan D.E. PAI-1 and atherothrombosis. J Thromb Haemost 2005; 3: 8: 1879-1883.
  43. Wang T.J., Gona P., Larson M.G., Toiler G.H., Levy D., Newton-Cheh C., Jacques P.F., Rifai N., Selhub J., Robins S.J., Benjamin E.J., D'Agostino R.B., Vasan R.S. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 25: 2631-2639.
  44. Weisel J.W. Fibrinogen and fibrin. Adv Protein Chem 2005; 70: 247-299.
  45. Whitworth J.A., Williamson P.M., Mangos G., Kelly J.J. Cardiovascular consequences of cortisol excess. Vasc Health Risk Manag 2005; 1: 4: 291-299.
  46. Whitworth J.A., Mangos G.J., Kelly J.J. Cushing, cortisol, and cardiovascular disease. Hypertension 2000; 36: 912-916.
  47. Wiman B., Andersson T., Hallqvist J., Reuterwall C., Ahlbom A., deFaire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 2000; 20: 8: 2019-2023.
  48. Yang C.Y., Chou C.W., Lin M.B., Wang L.W., Chen S.Y., Cheng H.M. Reccurent pulmonary embolism in an with Cushing's syndrome, adrenocortical adenoma, pheochromocytoma and prostate adenocarcinoma. J Clin Med Ass 2004; 67: 7: 360-365.
  49. Younge P.A., Wiles P.G., Shmidt D. Cushing's syndrome: still a potential killing disease. J R Soc Med 1995; 88: 174-175.
  50. Zacharieva S., Atanassova I., Nachev E., Orbetzova M., Kirilov G., Kalinov K., Shigarminova R. Markers of vascular function in hypertension due to Cushing's syndrome. Horm Metab Res 2005; 37: l: 36-39.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.